Activated injectable vitamin D and hemodialysis survival: a historical cohort study.

By M. Teng, M. Wolf, M. Norma Ofsthun, J. Lazarus, Miguel A. Hern'an, C. Camargo, R. Thadhani. Journal of the American Society of Nephrology, 2005

802 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. (2005, background): “Patients with CKD at all stages are at markedly increased risk for mortality (24), and hemodialysis patients who are treated with activated vitamin D preparations demonstrate improved survival (43).”
Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. (2007, background): “Recently, increased attention has focused on endocrine abnormalities in patients with CKD as a way to explain some of these associations.(6,7) For example, 1,25-dihydroxyvitamin D (1,25 OH2 D3) deficiency is known to occur during the progression of CKD because the final hydroxylation step of 25-hydr”
Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. (2006, result): “Similar to the study by Teng et al.13 as well as our previous studies,29–32 we did not include history of cardiovascular or other comorbidities as covariates.”
Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. (2011, neutral): “pounds compared with those not so treated (59).”